

## BIBLIOGRAPHY

- Ahmad, T., Valentovic, M. A. and Rankin, G. O. 2018, Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics, *Biochem Pharmacol*, **153**, 196-204.
- Arnaldo, P., Thompson, R. E., Lopes, M. Q., Suffys, P. N. and Santos, A. R. 2013, Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population, *The Malaysian journal of medical sciences : MJMS*, **20**, 13-23.
- Bode, C. 2010, The nasty surprise of a complex drug-drug interaction, *Drug Discov Today*, **15**, 391-5.
- Crettol, S., Petrovic, N. and Murray, M. 2010, Pharmacogenetics of Phase I and Phase II Drug Metabolism, *Current Pharmaceutical Design*, **16**, 204-219.
- Dasgupta, A. 2017, Pharmacogenomics of abused drugs. *Alcohol, Drugs, Genes and the Clinical Laboratory*. 1st ed. Houston, TX, USA: Elsevier.
- Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., *et al.* 2007, Impact of *CYP2B6* polymorphism on hepatic efavirenz metabolism in vitro, *Pharmacogenomics* **8**.
- Ehtisham, M., Wani, F., Wani, I., Kaur, P. and Nissar, S. 2016, Polymerase Chain Reaction (PCR): Back to Basics, *Indian Journal of Contemporary Dentistry*, **4**, 30.
- Ellison, C. A., Abou El-Ella, S. S., Tawfik, M., Lein, P. J. and Olson, J. R. 2012, Allele and genotype frequencies of *CYP2B6* and *CYP2C19* polymorphisms in Egyptian agricultural workers, *J Toxicol Environ Health A*, **75**, 232-41.
- Farell, E. M. and Alexandre, G. 2012, Bovine serum albumin further enhances the effects of organic solvents on increased yield of polymerase chain reaction of GC-rich templates, *BMC Research Notes*, **5**, 257.
- Filipstsova, O., Kobets, M., Kobets, J., Naboka, O., Koiro, O., Ochkur, A., *et al.* 2018, Distribution of *CYP2B6* 516G/T pharmacogenetically important polymorphism in the Ukrainian population, *Saudi Pharm J*, **26**, 651-655.
- Fura, A., Shu, Y.-Z., Zhu, M., Hanson, R. L., Roongta, V. and Humphreys, W. G. 2004, Discovering Drugs through Biological Transformation: Role of Pharmacologically Active Metabolites in Drug Discovery, *Journal of Medicinal Chemistry*, **47**, 4339-4351.
- Gariyban, L. and Avashia, N. 2013, Polymerase chain reaction, *J Invest Dermatol*, **133**, 1-4.
- Gatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., *et al.* 2007, Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 \*6 and \*26, *Clinical Infectious Diseases*, **45**, 1230-1237.
- Green, M. R. and Sambrook, J. 2019, *Nested Polymerase Chain Reaction (PCR)*, United States of America, John Inglis.

- Guengerich, F. P. 2001, Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity, *Chemical Research in Toxicology*, **14**, 611-650.
- Guengerich, F. P. 2008, Cytochrome P450 and Chemical Toxicology, *Chemical Research in Toxicology*, **21**, 70-83.
- Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., *et al.* 2005, Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study, *The Journal of Infectious Diseases*, **192**, 1931-1942.
- Hananta, L., Astuti, I., Sadewa, A. H., Alice, J., Hutagalung, J. and Mustofa 2018, The Prevalence of *CYP2B6* Gene Polymorphisms in Malaria-endemic Population of Timor in East Nusa Tenggara Indonesia, *Osong public health and research perspectives*, **9**, 192-196.
- Hassani Idrissi, H., El Khorb, N., Akoudad, A., Habbal, R. and Nadifi, S. 2018, Association of *CYP2B6* (G15631T) polymorphism with Clopidogrel resistance and genetic predisposition to Acute Coronary Syndromes (ACSs) in Morocco, *Gene Reports*, **11**, 244-249.
- Hofer, T., Ray, N., Wegmann, D. and Excoffier, L. 2009, Large allele frequency differences between human continental groups are more likely to have occurred by drift during range expansions than by selection, *Ann Hum Genet*, **73**, 95-108.
- Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeffeler, E., Schwab, M., *et al.* 2008, Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of *CYP2B6*\*6, is responsible for decreased expression and activity of *CYP2B6* in liver, *J Pharmacol Exp Ther*, **325**, 284-92.
- Hui, K. H., Lee, S. S. and Lam, T. N. 2016, Dose Optimization of Efavirenz Based on Individual *CYP2B6* Polymorphisms in Chinese Patients Positive for HIV, *CPT Pharmacometrics Syst Pharmacol*, **5**, 182-91.
- Ingelman-Sundberg, M. 2004, Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms, *Naunyn Schmiedebergs Arch Pharmacol*, **369**, 89-104.
- Ismail, S. and Essawi, M. 2012, Genetic polymorphism studies in humans, *Middle East Journal of Medical Genetics*, **1**, 57-63.
- Johansson, I. and Ingelman-Sundberg, M. 2011, Genetic polymorphism and toxicology--with emphasis on cytochrome p450, *Toxicol Sci*, **120**, 1-13.
- Joshi, M. and Deshpande 2010, Polymerase Chain Reaction: Methods, Principles and Application, *International Journal of Biomedical Research*, **5**, 81-97.
- Kang, M. J., Song, W. H., Shim, B. H., Oh, S. Y., Lee, H. Y., Chung, E. Y., *et al.* 2010, Pharmacologically Active Metabolites of Currently Marketed Drugs: Potential Resources for New Drug Discovery and Development, *Yakugaku Zasshi*, **130**, 1325-1337.
- Kassam, S., Meyer, P., Corfield, A., Mikuz, G. and Sergi, C. 2005, Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications, *Current Pharmacogenomics*, **3**, 237-245.

- Kebamo, S., Tesema, S. and Geleta, B. 2015, The Role of Biotransformation in Drug Discovery and Development, *Journal of Drug Metabolism and Toxicology*, **6**.
- Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., *et al.* 2003, Hepatic *CYP2B6* expression: gender and ethnic differences and relationship to *CYP2B6* genotype and CAR (constitutive androstane receptor) expression, *J Pharmacol Exp Ther*, **307**, 906-22.
- Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M., *et al.* 2004, Multiple novel nonsynonymous *CYP2B6* gene polymorphisms in Caucasians: demonstration of phenotypic null alleles, *J Pharmacol Exp Ther*, **311**, 34-43.
- Levrán, O., Peles, E., Hamon, S., Randesi, M., Adelson, M. and Kreek, M. J. 2013, *CYP2B6* SNPs are associated with methadone dose required for effective treatment of opioid addiction, *Addict Biol*, **18**, 709-16.
- Lucena-Aguilar, G., Sanchez-Lopez, A. M., Barberan-Aceituno, C., Carrillo-Avila, J. A., Lopez-Guerrero, J. A. and Aguilar-Quesada, R. 2016, DNA Source Selection for Downstream Applications Based on DNA Quality Indicators Analysis, *Biopreserv Biobank*, **14**, 264-70.
- Lum, J. K. and Cann, R. L. 1998, mtDNA and Language Support a Common Origin of Micronesians and Polynesians in Island Southeast Asia, *American Journal Of Physical Anthropology*, **105**, 109-119.
- Maekawa, K., Adachi, M., Matsuzawa, Y., Zhang, Q., Kuroki, R., Saito, Y., *et al.* 2017, Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9, *Biochemistry*, **56**, 5476-5480.
- Marchelaona, R. 2016, Korelasi Polimorfisme Genetik CYP2A6 dan *CYP2B6* Dengan Kuantitas Merokok pada Individu Suku Jawa,
- Marmioli, N. and Maestri, E. 2007, Polymerase chain reaction (PCR), 147-187.
- Martiny, V. Y. and Miteva, M. A. 2013, Advances in molecular modeling of human cytochrome P450 polymorphism, *J Mol Biol*, **425**, 3978-92.
- Mattei, J., Parnell, L. D., Lai, C. Q., Garcia-Bailo, B., Adiconis, X., Shen, J., *et al.* 2009, Disparities in allele frequencies and population differentiation for 101 disease-associated single nucleotide polymorphisms between Puerto Ricans and non-Hispanic whites, *BMC Genet*, **10**, 45.
- Mehlotra, R. K., Ziats, M. N., Bockarie, M. J. and Zimmerman, P. A. 2006, Prevalence of *CYP2B6* alleles in malaria-endemic populations of West Africa and Papua New Guinea, *Eur J Clin Pharmacol*, **62**, 267-75.
- Musa, N., Zulkafli, M. I., Talib, N., Mohamad, N., Fauzi, H. and Ismail, R. 2012, Haplotypes frequencies of *CYP2B6* in Malaysia, *J Postgrad Med*, **58**, 235-41.
- Musa, N. B. 2017, Genetics and Inter-Individual Variability of Methadone Metabolism, *Dissertation*, Universiti Sains Malaysia, Malaysia
- Namipashaki, A., Razaghi-Moghadam, Z. and Ansari-Pour, N. 2015, The Essentiality of Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based Genetic Association Studies, *Cell Journal*, **17**, 187-192.
- Neary, M. and Owen, A. 2017, Pharmacogenetic considerations for HIV treatment in different ethnicities: an update, *Expert Opin Drug Metab Toxicol*, **13**, 1169-1181.

- Nebert, D. W. and Russell, D. W. 2002, Clinical importance of the cytochromes P450, *The Lancet*, **360**, 1155-1162.
- Nolte, F. S., Hirschhorn, J. W. and Hill, C. E. 2017, Polymerase Chain Reaction and Other Nucleic Acid Amplification Technology. In: Mcpherson, R. A. ,Pincus, M. R. (eds.) *Henry's Clinical Diagnosis and Management by Laboratory Methods*. Twenty-Third ed.: Elsevier.
- Nussbaum, R. L., Mcinnes, R. R. and Willard, H. F. 2016, Genetic Variation in Populations. In: Nussbaum, R. L., Mcinnes, R. R. ,Willard, H. F. (eds.) *Thompson & Thompson Genetics In Medicine, Eighth Edition*. 8th ed. Philadelphia: Elsevier.
- Patil, J. 2015, Pharmacogenetics and Pharmacogenomics: A Brief Introduction, *J Pharmacovigilance*, **3**.
- Peko, S. M., Gueye, N. S. G., Vouvongui, C., Koukouikila-Koussounda, F., Kobawila, S. C., Nderu, D., *et al.* 2019, Cytochrome P450 *CYP2B6\*6* distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection, *Int J Infect Dis*, **82**, 111-116.
- Penzak, S., Kabuye, G., Mugenyi, P., Mbamanya, F., Natarajan, V., Alfaro, R., *et al.* 2007, Cytochrome P450 2B6 (*CYP2B6*) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda, *HIV Medicine*, **8**, 86-91.
- Pimentel, M. R., Molina, G., Dionísio, A. P., Maróstica Junior, M. R. and Pastore, G. M. 2011, The Use of Endophytes to Obtain Bioactive Compounds and Their Application in Biotransformation Process, *Biotechnology Research International*, **2011**, 576286.
- Pincus, M. R., Lifshitz, M. S. and Bock, J. L. 2017, Analysis: Principles of Instrumentation. In: Mcpherson, R. A. ,Pincus, M. R. (eds.) *Henry's Clinical Diagnosis and Management by Laboratory Methods*. Twenty-Third ed.: Elsevier.
- Porcelli, S., Fabbri, C., Spina, E., Serretti, A. and De Ronchi, D. 2011, Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism, *Expert Opinion on Drug Metabolism & Toxicology*, **7**, 1101-1115.
- Powers, V., Ward, J. and Gompels, M. 2009, *CYP2B6* G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation, *HIV Med*, **10**, 520-3.
- Raccor, B. S., Claessens, A. J., Dinh, J. C., Park, J. R., Hawkins, D. S., Thomas, S. S., *et al.* 2012, Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo, *Drug Metab Dispos*, **40**, 54-63.
- Rakhmanina, N. Y. and Anker, J. N. V. D. 2010, Efavirenz in the therapy of HIV infection, *Expert Opin. Drug Metab. Toxicol.*, **6**.
- Relling, M. V. and Giacomini, K. M. 2011, Pharmacogenetics. In: Brunton, L. L., Chabner, B. A. ,Knollmann, B. C. (eds.) *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. United States: The McGraw-Hill Companies.
- Rittie, L. and Perbal, B. 2008, Enzymes used in molecular biology: a useful guide, *J Cell Commun Signal*, **2**, 25-45.
- Rodriguez-Antona, C. and Ingelman-Sundberg, M. 2006, Cytochrome P450 pharmacogenetics and cancer, *Oncogene*, **25**, 1679-91.

- Scibona, P., Vazquez, C., Cajal, A. R., Argibay, P. F. and Belloso, W. H. 2015, Prevalence of *CYP2B6* polymorphisms in Argentinians: the role of genetic testing, *Genet Mol Res*, **14**, 16594-9.
- Singh, D., Kashyap, A., Pandey, R. V. and Saini, K. S. 2011, Novel advances in cytochrome P450 research, *Drug Discov Today*, **16**, 793-9.
- Smith, K. 2002, Genetic Polymorphism and SNPs, *Genotyping, Haplotype Assembly Problem, Haplotype Map, Functional Genomics and Proteomics*.
- Sudoyo, H. 2015, Genetika Melanesia di Nusantara. In: Abdullah, T. ,Paeni, M. (eds.) *Diaspora Melanesia di Nusantara*. Jakarta: Kementerian Pendidikan dan Kebudayaan.
- Sukhumsirichart, W. 2018, Polymorphisms. In: Liu, Y. (ed.) *Genetic Diversity and Disease Susceptibility*. InTech.
- Telenti, A. and Zanger, U. M. 2008, Pharmacogenetics of anti-HIV drugs, *Annu Rev Pharmacol Toxicol*, **48**, 227-56.
- Tesema, S., Kebamo, S. and Geleta, B. 2016, Pharmacogenetics and Pharmacogenomics: Applications in Drug Development and Therapeutics, **2**, 165-186.
- Turnpenny, P. D. and Ellard, S. 2017, Population and Mathematical Genetics. In: Turnpenny, P. D. ,Ellard, S. (eds.) *Emery's Elements of Medical Genetics*. 15th ed. China: Elsevier.
- Turpeinen, M. and Zanger, U. M. 2012, Cytochrome P450 2B6: function, genetics, and clinical relevance, *Drug Metabol Drug Interact*, **27**, 185-97.
- Veenemans, J., Jansen, E. J. S., Baidjoe, A. Y., Mbugi, E. V., Demir, A. Y., Kraaijenhagen, R. J., *et al.* 2011, Effect of  $\alpha$ -thalassaemia on episodes of fever due to malaria and other causes: a community-based cohort study in Tanzania, *Malaria Journal*, **10**, 280.
- Winter, P. C. 2005, Polymerase Chain Reaction (PCR).
- Xie, H. J., Yasar, U., Lundgren, S., Griskevicius, L., Terelius, Y., Hassan, M., *et al.* 2003, Role of polymorphic human *CYP2B6* in cyclophosphamide bioactivation, *Pharmacogenomics J*, **3**, 53-61.
- Yuce-Artun, N., Kose, G. and Suzen, H. S. 2014, Allele and genotype frequencies of *CYP2B6* in a Turkish population, *Mol Biol Rep*, **41**, 3891-6.
- Zanger, U. M. and Klein, K. 2013, Pharmacogenetics of cytochrome P450 2B6 (*CYP2B6*): advances on polymorphisms, mechanisms, and clinical relevance, *Front Genet*, **4**, 24.
- Zanger, U. M. and Schwab, M. 2013, Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation, *Pharmacol Ther*, **138**, 103-41.
- Zhang, H., Sridar, C., Kenaan, C., Amunugama, H., Ballou, D. P. and Hollenberg, P. F. 2011, Polymorphic variants of cytochrome P450 2B6 (*CYP2B6.4-CYP2B6.9*) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (*CYP2B6.8*) impairs formation of a functional cytochrome p450-reductase complex, *J Pharmacol Exp Ther*, **338**, 803-9.

- Zhou, G., Li, Q., Huang, L., Wu, Y., Wu, M. and Wang, W. C. 2016, Quality Analysis of DNA from Cord Blood Buffy Coat: The Best Neonatal DNA Source for Epidemiological Studies?, *Biopreserv Biobank*, **14**, 165-71.
- Zhou, S. F., Liu, J. P. and Chowbay, B. 2009, Polymorphism of human cytochrome P450 enzymes and its clinical impact, *Drug Metab Rev*, **41**, 89-295.
- Zhou, Y., Ingelman-Sundberg, M. and Lauschke, V. M. 2017, Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects, *Clin Pharmacol Ther*, **102**, 688-700.